|Fondaparinux and acute coronary syndromes: update on the OASIS 5-6 studies.|
|Jump to Full Text|
|PMID: 20407625 Owner: NLM Status: MEDLINE|
|Anticoagulant therapy is a major component in the management of acute coronary syndromes (ACS). Four anticoagulant agents are currently commercially available for ACS, namely unfractionated heparin (UFH), enoxaparin, bivalirudin and fondaparinux. We describe the advantages of fondaparinux and the reasons that have hampered its uptake into routine management of ACS. Fondaparinux was shown to be efficacious in the prevention of deep vein thrombosis vs low-molecular-weight heparins, while in the setting of venous thrombo-embolic disease, it was shown to be noninferior to enoxaparin and UFH. Two pivotal studies have demonstrated the efficacy of fondaparinux as an anticoagulant in the setting of ACS, namely OASIS-5 in non-ST elevation ACS, and OASIS-6 in ST elevation myocardial infarction (MI). In OASIS-5, fondaparinux was shown to be noninferior to enoxaparin in terms of death, MI or refractory ischemia at 9 days. Furthermore, a 50% reduction in bleeding complications was obtained with fondaparinux vs enoxaparin, leading to a risk reduction for death. In OASIS-6, fondaparinux was shown to be superior to the comparator (UFH or placebo). European and North American guidelines give fondaparinux a Grade 1A and 1B recommendation respectively, but uptake of fondaparinux in routine practice has been slow. We explore reasons for this, such as prevailing doubts about the efficacy of fondaparinux in the setting of angioplasty, the problem of catheter thrombosis, and the lack of antidote in case of bleeding complications. With the exception of primary angioplasty, fondaparinux is as effective as enoxaparin or UFH, but is also associated with a considerable reduction in bleeding complications, and thus, an undeniable net clinical benefit.|
Related Documents :
|15686785 - Treatment of left ventricular thrombi with a low molecular weight heparin.
12439435 - Use of glycoprotein iib/iiia platelet inhibitors in peripheral vascular interventions.
15660045 - Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (...
16370925 - Argatroban, a direct thrombin inhibitor for heparin-induced thrombocytopaenia: present ...
22267375 - Effect of elective percutaneous coronary intervention on left ventricular function in p...
10412645 - The role of apoptosis in dilated cardiomyopathy.
|Type: Journal Article Date: 2010-04-15|
|Title: Vascular health and risk management Volume: 6 ISSN: 1178-2048 ISO Abbreviation: Vasc Health Risk Manag Publication Date: 2010|
|Created Date: 2010-04-21 Completed Date: 2011-01-27 Revised Date: 2013-05-29|
Medline Journal Info:
|Nlm Unique ID: 101273479 Medline TA: Vasc Health Risk Manag Country: New Zealand|
|Languages: eng Pagination: 179-87 Citation Subset: IM|
|Department of Cardiology, University Hospital Jean-Minjoz, Besançon, France. firstname.lastname@example.org|
|APA/MLA Format Download EndNote Download BibTex|
Acute Coronary Syndrome
Anticoagulants / adverse effects, therapeutic use*
Catheterization / adverse effects
Enoxaparin / therapeutic use
Peptide Fragments / therapeutic use
Polysaccharides / adverse effects, therapeutic use*
Recombinant Proteins / therapeutic use
Thrombosis / etiology
|0/Anticoagulants; 0/Enoxaparin; 0/Hirudins; 0/Peptide Fragments; 0/Polysaccharides; 0/Recombinant Proteins; 128270-60-0/bivalirudin; J177FOW5JL/fondaparinux|
Journal ID (nlm-ta): Vasc Health Risk Manag
Journal ID (publisher-id): Vascular Health and Risk Management
Publisher: Dove Medical Press
? 2010 Schiele, publisher and licensee Dove Medical Press Ltd.
Received Day: 24 Month: 3 Year: 2010
collection publication date: Year: 2010
Print publication date: Year: 2010
Electronic publication date: Day: 15 Month: 4 Year: 2010
Volume: 6First Page: 179 Last Page: 187
PubMed Id: 20407625
Publisher Id: vhrm-6-179
|Fondaparinux and acute coronary syndromes: update on the OASIS 5?6 studies|
|Department of Cardiology, University Hospital Jean-Minjoz, Besan?on, France
|Correspondence: Correspondence: Fran?ois Schiele, Department of Cardiology, Centre Hospitalier Universitaire Jean Minjoz, Universit? de Franche Comte, EA 3920, Boulevard Fleming, 25000 Besan?on, France, Tel +33.381.668.539, Fax +33.381.668.582, Email
Anticoagulant therapy is the one of the cornerstones in the management of acute coronary syndromes (ACS), in both invasive and noninvasive strategies.1,2 Currently, four anticoagulant agents are commercially available for the treatment of ACS, namely, unfractionated heparin (UFH), enoxaparin, bivalirudin, and fondaparinux (pentasaccharide). Each of these agents has its different advantages and disadvantages, and there are also differing levels of evidence supporting the efficacy and safety of each. In the two years since fondaparinux has become commercially available, its place in the management of ACS remains minor, as shown by the results of the Euro Heart Survey ACS-3 registry. This article aims to describe the advantages of fondaparinux, both theoretical and proven, as well as the reasons why its uptake into routine management of ACS has been moderate.
UFH remains the most frequently used anticoagulant agent in the setting of ACS. It has both anti-IIa and anti-Xa effects, and apart from being inexpensive, its further advantages are that it is not contra-indicated in case of severe renal insufficiency, it has a short half-life, and it can be neutralized if necessary using protamine sulfate. The main disadvantage of UFH is that its action is neither stable nor predictable, with the result that frequent monitoring and dose adjustments are necessary, even with intravenous use.
Low-molecular-weight heparins (LMWH), such as enoxaparin, have an excellent bioavailability, preferential anti-Xa activity, and can be used by intravenous or subcutaneous route. They have been shown to be superior to UFH in case of ?conservative? management strategy3,4 or in the setting of ST elevation myocardial infarction (STEMI) treated by thrombolytic therapy.5 In the setting of non-ST elevation ACS (NSTE-ACS) submitted to angioplasty, enoxaparin has comparable efficacy to UFH, but with more frequent hemorrhagic complications6 and has never been tested in the setting of primary angioplasty for STEMI.
Bivalirudin represents a third group of anticoagulant agents, namely direct thrombin inhibitors. Bivalirudin can be administered intravenously, has a predictable efficacy, a very short half-life, and no interaction with platelet function. All these qualities make bivalirudin an attractive alternative for use in the setting of angioplasty. Two large randomized trials have compared bivalirudin to a combination of UFH and anti-GP IIb/IIIa inhibitors, and showed that efficacy was similar, with fewer bleeding events under bivalirudin therapy in the setting of NSTE-ACS,7 and a reduction in mortality in the setting of STEMI treated by primary angioplasty.8
Lastly, fondaparinux is a synthetic pentasaccharide that reproduces the sequence in heparins that mediates their interaction with antithrombin. It has a pure and selective anti-Xa activity through its link with antithrombin. The inhibition of thrombin generation is dose-dependent, but without inhibiting the actual thrombin molecule. The mechanism of action of fondaparinux is unique, in that the fondaparinux molecule attaches itself to the antithrombin, thereby changing its structure and allowing the neutralization of factor Xa. After inhibition of one factor Xa molecule, the fondaparinux is released in its active form by the antithrombin, and can thus recirculate and attach to another antithrombin molecule to perform another round of inhibition of factor Xa. This cycle serves to amplify the effect of fondaparinux. Compared to UFH, the affinity of fondaparinux for antithrombin is 15 times higher, and the inhibition of thrombin generation is considerably increased through the anti-Xa activity.9 The bioavailability of fondaparinux is 100% after subcutaneous injection, and its half-life is around 17 hours. Since it is eliminated primarily through the renal route, it is insensitive to inactivation by platelet proteins, which neutralise heparin. It causes no formation of heparin-PF4 complexes, and does not expose the patient to a risk of heparin-induced thrombocytopenia.
Fondaparinux was shown to be efficacious in the prevention of deep vein thrombosis in the setting of major orthopedic surgery compared with usual therapy with LMWH.10,11 In the setting of venous thrombo-embolic disease, deep vein thrombosis, or pulmonary embolism, fondaparinux was shown to be noninferior to enoxaparin and UFH, respectively. On the arterial side, the anticoagulant efficacy of fondaparinux was demonstrated in a pilot study using primary angioplasty as a model of arterial thrombosis.12 Phase II studies were carried out in both forms of ACS, namely STEMI13 and NSTE-ACS.14 In this latter study, the 2.5 mg once-daily dose was shown to have superior efficacy than higher doses of fondaparinux and enoxaparin, with a lower rate of bleeding. The 2.5 mg dose was then selected for use in phase III randomized trials in ACS with and without ST elevation. The two pivotal studies of fondaparinux in this setting were OASIS-5,15 which included 20,078 patients with NSTE-ACS, and OASIS-6,16 which included 12,092 patients with STEMI. In OASIS-5, fondaparinux was shown to be noninferior to enoxaparin in terms of the main efficacy endpoints (death, MI, refractory ischemia) at 9 days. More importantly, a reduction of almost 50% in bleeding complications was obtained with fondaparinux compared with enoxaparin (2.2% vs 4.1% respectively). This reduction in bleeding had a considerable effect on the rate of ischemic events, with a significant reduction in death at 30 days and 6 months, but also with significant reductions in the combined endpoints of death/MI and death/MI/stroke at 30 days and 6 months. It is important to underline that this benefit was observed in all the predefined subgroups, in particular among the elderly, females, patients with renal failure, diabetes patients, and also in all risk categories (low, medium, and high risk). Finally, and perhaps most important of all, the benefit was consistent in patients submitted to coronary angioplasty, in whom fondaparinux was shown to be noninferior at 9 days compared with enoxaparin in terms of the main efficacy endpoint, but with a considerable reduction in bleeding complications. As a result, the net clinical benefit is significantly greater with fondaparinux than with enoxaparin.
In the overall population of the OASIS-6 study, fondaparinux was shown to be superior to the comparator (UFH or placebo). In OASIS-6, patients were randomized to two strata, depending on whether heparin was indicated or not (in stratum 1, the comparator was placebo and in stratum 2, the comparator was UFH). Not only was a reduction in mortality or re-infarction observed with fondaparinux (7.4% vs 8.9%, P = 0.003 at 9 days, 9.7% vs 11.2%, P = 0.008 at 30 days and 13.4% vs 14.8%, P = 0.008 at 6 months), but there was also a reduction in mortality (6.1% vs 7.0%, P = 0.04 at 9 days, 7.8% vs 8.9%, P = 0.03 at 30 days and 10.5% vs 11.6%, P = 0.03 at 6 months). In parallel, there was a trend towards fewer major bleedings, and significantly less tamponnade in the fondaparinux group. These results showing a reduced ischemic risk without an increase in bleeding risk were observed in patients who were not reperfused, in patients submitted to thrombolytic therapy, but not in patients treated by primary angioplasty.
Since the results of the OASIS-5 and OASIS-6 studies were reported, the guidelines for the management of STEMI17 and NSTE-ACS1,18,19 issued by the ESC, ACC-AHA and ACCP have all been updated. Although based on the same scientific evidence, the levels of recommendation in the ESC and American guidelines are not exactly the same, because different criteria were taken into consideration to decide on the level of recommendation (Table 1).
In the guidelines issued by the ESC and the ACCP, fondaparinux enjoys a grade 1A recommendation in the setting of NSTE-ACS, except in case of urgent angioplasty. The ACC-AHA guidelines give a grade 1A recommendation for fondaparinux in case of conservative strategy, but grade 1B in case of invasive strategy, and do not make any distinction with urgent angioplasty. In the setting of STEMI, fondaparinux is recommended over no anticoagulation, in patients not undergoing reperfusion, in case of thrombolytic therapy, but not in case of primary angioplasty (Figure 1). The ACCP recommendations largely follow those of the ESC, recommending against the use of fondaparinux in case of primary angioplasty. In case of angioplasty in patients pretreated with fondaparinux, an additional bolus of 50 to 100 IU/kg of UFH is recommended.
Finally, the ESC guidelines for the management of NSTE-ACS accord particular attention to patients at high risk of bleeding, namely women, elderly patients, patients with renal failure and those with baseline anemia. The use of fondaparinux is recommended in these groups on the basis of its superior efficacy?safety profile.
Despite the favorable results of the OASIS-5 and 6 trials and the strong recommendations of the European and North American guidelines, which give fondaparinux a grade IA or IB recommendation in NSTE-ACS, the use of fondaparinux in this setting has not been as high as might be expected, particularly in centers with angioplasty facilities on site. The Euro Heart Survey ACS III registry shows that fondaparinux is used in only 3% of patients, compared with 43% for UFH and 53% for enoxaparin. To date, there has been only one study reporting the routine use of fondaparinux in ACS. In a multicenter registry of over 2800 patients, the uptake of fondaparinux in routine practice 2 years after its first availability on the market reportedly depends heavily on local factors. Centers with cathlabs on site were reluctant to use fondaparinux routinely, preferring UFH or enoxaparin20 (Figure 2). The reasons for this choice are manifold, and include prevailing doubts about the efficacy of fondaparinux in the setting of angioplasty, the problem of catheter thrombosis, and the lack of antidote in case of bleeding complications.
- The efficacy and safety of fondaparinux in ACS (STEMI or NSTE-ACS) has been studied in a pooled analysis of the OASIS-5 and 6 data.21 In patients who underwent invasive strategy, fondaparinux reduced mortality at 30 days, the combined endpoint (death, MI, or stroke), and major bleeding, compared with UFH or enoxaparin.
- In NSTE-ACS, results from angioplasty under fondaparinux therapy were studied in the OASIS-5 trial, in which 64% of patients underwent invasive diagnostic exam during the treatment phase, and 31% (6238) underwent angioplasty within the first 72 hours. This predefined subgroup of patients with invasive strategy was analyzed separately.22 In this situation, the benefit obtained with fondaparinux compared with enoxaparin was similar to that observed in the main cohort, insofar as the rate of ischemic events was identical at 9 days, and there was a significant reduction in major bleeding (1.6% vs 3.8%, hazard ration [HR] 0.42, P < 0.001). Furthermore, the net clinical benefit was superior with fondaparinux (rate of death, infarction, stroke or major bleeding at 9 days of 8.2% vs 10.4%, HR = 0.78, P = 0.004) (Table 2). Thus, in the context of an early invasive strategy, the results plead in favor of fondaparinux. It is noteworthy that the reduction in bleeding complications appeared very early, with a reduction of 35% to 40% from day 1 to day 8 (Table 3).
- In the setting of STEMI, the results of OASIS-6 are also globally in favor of fondaparinux. In stratum II of this study (ie, compared to patients treated with UFH), the rate of ischemic events was not significantly different between treatment arms. However, in the group of patients who underwent primary angioplasty, there was a tendency towards an excess of death at 30 days (6.1% with fondaparinux vs 5.1% with UFH, P = 0.19) (Figure 1 and 3). Although this trend was not significant at 30 days, and was not observed at all at the other timepoints (9 days and 6 months), it could explain why fondaparinux is not recommended for use in primary angioplasty in the setting of STEMI.17,23 Conversely, in the population of 2666 patients with STEMI who underwent angioplasty other than by primary percutaneous coronary intervention (PCI), outcome was favorable under fondaparinux therapy compared with UFH (rate of death or infarction of 11.5% vs 13.8% respectively, P = 0.08), with a trend towards fewer major bleeding events.
This is a second element that may explain the reluctance of certain interventional cardiologists to use fondaparinux in angioplasty.
- Although it was not one of the predefined endpoints, the OASIS-5 and -6 investigators reported several occurrences of catheter thrombus with fondaparinux. This problem had not been encountered during the pilot dose-finding study for fondaparinux,14 but in OASIS-5, although the rate of coronary occlusion was comparable in both arms, the rate of catheter thrombus was higher with fondaparinux than with enoxaparin (0.9% vs 0.4%, P < 0.001). This was confirmed versus UFH in OASIS-6 in the setting of primary angioplasty (0% vs 22%, P < 0.001). An amendment to the OASIS-5 protocol authorized the use of a bolus of UFH at the time of angioplasty to prevent the occurrence of catheter thrombus. This strategy was applicable in 793 OASIS-5 patients under fondaparinux, but was actually applied in only 75 patients, at a median dose of 50 IU/kg, and only one case of catheter thrombus was subsequently observed.
- The mechanism leading to the formation of catheter thrombus under fondaparinux therapy is not clearly elucidated. It is possible that the thrombus formation is facilitated by kallikrein, which can lead to activation of factor XIIa. In vitro studies have shown that activation of factor XIIa can generate thrombin formation after contact with artificial surfaces such as catheters24 and that compared with heparin or bivalirudin, fondaparinux is less efficacious in preventing catheter thrombosis.25
- The use of an additional bolus of UFH during angioplasty seems to be an effective solution in the case of angioplasty under fondaparinux therapy. However, although the association of different anticoagulants during angioplasty was reported to be safe in terms of the association of bivalirudin and UFH,26 the association of enoxaparin with UFH was reportedly associated with an excess of hemorrhagic events, death, or MI in the SYNERGY study.27
In the ESC guidelines for NSTE-ACS, three situations are outlined in terms of invasive strategy: elective invasive strategy, early invasive strategy with angioplasty and revascularization within 72 hours of admission, and finally, the so-called ?urgent invasive strategy?, which is the least common situation, characterized by the persistence of chest pain with ECG changes, hemodynamic instability or severe arrhythmias. This situation requires immediate angiography and urgent angioplasty (Figure 4). The guidelines stipulate that in an urgent invasive strategy, fondaparinux should not be used, whereas it is indicated as the anticoagulant of choice in the other situations. It is thus likely that some confusion exists between ?early invasive? and ?urgent invasive? strategies, particularly since the ACC-AHA guidelines do not distinguish these two clinical situations.28,29
Although fondaparinux has been shown to be safer than UFH and enoxaparin, the fact that it cannot be neutralized remains a source of concern, particularly since its half-life is quite long. The use of recombinant factor VIIa to counteract major bleeding has been described in other types of coagulation disorders.30,31 In patients treated with fondaparinux, the use of recombinant factor VIIa (Novo7?) was studied among 16 healthy volunteers. After injection of 10 mg of fondaparinux, normalization of the endogenous thrombin potential was obtained 2 to 6 hours after administration of 90 ?g/kg of factor VIIa, suggesting that there is potential for this formula to be used in case of bleeding under fondaparinux.32
The factors that determine the choice of anticoagulant in any given situation are manifold, and thus, it is difficult to list exhaustively all the reasons why fondaparinux is or is not used in patients with NSTE-ACS. Nonetheless, it is like that medico-legal and/or economic factors, as well as a generalized reluctance to change, are responsible for the slow uptake of fondaparinux, to the same extent as the scientific reasons. In this context, the main reason why fondaparinux is not used in the United States is probably because it is not approved for use in ACS by the US Food and Drug Administration, despite the scientific evidence in its favor provided by the OASIS-5 and 6 studies. The increasing use of a radial approach for coronary angiography and angioplasty is an efficacious method of reducing bleeding risk, that probably also minimizes the potential benefit of fondaparinux over heparins. Conversely, the low cost and synthetic nature of fondaparinux are characteristics that should plead highly in its favor. Indeed, the contamination with chondroitin sulphate of tissue extracts used to manufacture heparins, brought to light by a series of fatal adverse reactions in 200833 was allegedly voluntary; underlining once again the advantage of synthetic molecules over those fabricated using tissue extracts.
Fondaparinux is an anticoagulant that presents particular advantages for use in the setting of acute coronary syndromes, and its efficacy and safety have been convincingly demonstrated in two randomized trials that included a huge number of patients across the spectrum of clinical situations represented by ACS. With the exception of primary angioplasty, fondaparinux is as effective as enoxaparin or UFH, but is also associated with a considerable reduction in bleeding complications, and thus, an undeniable net clinical benefit. The rate of use of fondaparinux in routine practice is as yet poorly documented. On the assumption that reluctance to use fondaparinux is unjustified, bearing in mind that European and North American guidelines recommend fondaparinux as the anticoagulant of choice, particularly when there is a high risk of bleeding, and in view of its simplicity of use (single dose, one daily injection, no monitoring), fondaparinux could become one of, if not the most, widely used anticoagulants in ACS. However, there remains the problem of patients with renal dysfunction, who present a high risk of both thrombosis and bleeding, and thus do not qualify for treatment with any of the ?new? anticoagulants available.
The author declares no conflicts of interest.
|1..||Anderson JL,Adams CD,Antman EM,et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction-Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency MedicineJ Am Coll CardiolYear: 2007507652726|
|2..||Bassand JP,Hamm CW,Ardissino D,et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromesEur Heart JYear: 200728131598166017569677|
|3..||Cohen M,Demers C,Gurfinkel EP,et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study GroupN Engl J MedYear: 199733774474529250846|
|4..||Antman EM,McCabe CH,Gurfinkel EP,et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trialCirculationYear: 1999100151593160110517729|
|5..||Antman EM,Morrow DA,McCabe CH,et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarctionN Engl J MedYear: 2006354141477148816537665|
|6..||Ferguson JJ,Califf RM,Antman EM,et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trialJAMAYear: 20042921455415238590|
|7..||Stone GW,McLaurin BT,Cox DA,et al. Bivalirudin for patients with acute coronary syndromesN Engl J MedMonth: 11 Day: 23 Year: 2006355212203221617124018|
|8..||Stone GW,Witzenbichler B,Guagliumi G,et al. Bivalirudin during primary PCI in acute myocardial infarctionN Engl J MedYear: 2008358212218223018499566|
|9..||Petitou M,Herault JP,Bernat A,et al. Synthesis of thrombin-inhibiting heparin mimetics without side effectsNatureYear: 1999398672641742210201371|
|10..||Bauer KA,Eriksson BI,Lassen MR,Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgeryN Engl J MedYear: 2001345181305131011794149|
|11..||Eriksson BI,Bauer KA,Lassen MR,Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgeryN Engl J MedYear: 2001Month: 11 Day: 1 345181298130411794148|
|12..||Vuillemenot A,Schiele F,Meneveau N,et al. Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent?a pilot study in the setting of coronary angioplastyThromb HaemostYear: 199981221422010063994|
|13..||Coussement PK,Bassand JP,Convens C,et al. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE studyEur Heart JYear: 200122181716172411511121|
|14..||Mehta SR,Steg PG,Granger CB,et al. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot TrialCirculationYear: 2005111111390139715781750|
|15..||Yusuf S,Mehta SR,Chrolavicius S,et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromesN Engl J MedYear: 2006354141464147616537663|
|16..||Yusuf S,Mehta SR,Chrolavicius S,et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation mycardial infarction: the OASIS-6 randomized trialJAMAYear: 2006295131519153016537725|
|17..||Van de Werf F,Bax J,Betriu A,et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of CardiologyEur Heart JYear: 200829232909294519004841|
|18..||Bassand JP,Hamm CW,Ardissino D,et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of CardiologyEur Heart JYear: 200728131598166017569677|
|19..||Harrington RA,Becker RC,Cannon CP,et al. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)ChestYear: 20081336 Suppl670S707S18574276|
|20..||Schiele F,Meneveau N,Seronde MF,et al. Routine use of fondaparinux in acute coronary syndromes: a 2-year multicenter experienceAm Heart JYear: 2010159219019820152216|
|21..||Mehta SR,Boden WE,Eikelboom JW,et al. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trialsCirculationYear: 2008118202038204618955665|
|22..||Mehta SR,Granger CB,Eikelboom JW,et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trialJ Am Coll CardiolYear: 200750181742175117964037|
|23..||Goodman SG,Menon V,Cannon CP,Steg G,Ohman EM,Harrington RA. Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)ChestYear: 20081336 Suppl708S775S18574277|
|24..||Stief TW. Kallikrein activates prothrombinClin Appl Thromb HemostYear: 2008141979818160576|
|25..||Maegdefessel L,Buerke M,Schubert S,et al. Comparison of bivalirudin, enoxaparin, and unfractionated heparin in preventing cardiac catheter thrombosis. Results of an in-vitro studyThromb HaemostYear: 2008100469369818841294|
|26..||Mehran R,Pocock SJ,Stone GW,et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trialEur Heart JYear: 200930121457146619351691|
|27..||Cohen M,Mahaffey KW,Pieper K,et al. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromesJ Am Coll CardiolYear: 20064871346135417010793|
|28..||Eikelboom J,Guyatt G,Hirsh J. Guidelines for anticoagulant use in acute coronary syndromesLancetYear: 200837196241559156118468530|
|29..||Bassand JP,Hamm C. Guidelines for anticoagulant use in acute coronary syndromesLancetYear: 20083729638532533author reply 533?53418707977|
|30..||Kubisz P,Stasko J. Recombinant activated factor VII in patients at high risk of bleedingHematologyYear: 2004956317332|
|31..||Haverkamp D,Hutten BA,Buller HR,Gallus AS,Lensing AW,Prins MH. The use of specific antidotes as a response to bleeding complications during anticoagulant therapy for venous thromboembolismJ Thromb HaemostYear: 200311697312871541|
|32..||Bijsterveld NR,Moons AH,Boekholdt SM,et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteersCirculationYear: 2002106202550255412427650|
|33..||Kishimoto TK,Viswanathan K,Ganguly T,et al. Contaminated heparin associated with adverse clinical events and activation of the contact systemN Engl J MedYear: 2008358232457246718434646|
Keywords: fondaparinux, OASIS, acute coronary syndromes.
Previous Document: Orphanhood and Schooling in South Africa: Trends in the vulnerability of orphans between 1993 and 20...
Next Document: Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes.